Education
About Us
Working with TipRanks
Follow Us
Medicinova (MNOV)
NASDAQ:MNOV
MNOV Stock Chart & Stats
$1.47
-$0.10(-4.76%)
At close: 4:00 PM EST
$1.47
-$0.10(-4.76%)
Day’s Range― - ―
52-Week Range$1.13 - $2.24
Previous CloseN/A
Volume15.80K
Average Volume (3M)1.79M
Market Cap
$72.74M
Enterprise ValueN/A
Total Cash (Recent Filing)$32.56M
Total Debt (Recent Filing)$255.15K
Price to Earnings (P/E)―
Beta0.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding49,146,248
10 Day Avg. Volume177,340
30 Day Avg. Volume1,788,408
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)1.96
Price to Sales (P/S)0.00
P/FCF Ratio-9.68
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.5
Revenue Forecast (FY)N/A
Medicinova News
MNOV FAQ
What was Medicinova’s price range in the past 12 months?
Medicinova lowest stock price was $1.13 and its highest was $2.24 in the past 12 months.
What is Medicinova’s market cap?
Medicinova’s market cap is $72.74M.
When is Medicinova’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medicinova’s earnings last quarter?
Medicinova released its earnings results on Jul 27, 2022. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.087 by -$0.063.
Is Medicinova overvalued?
According to Wall Street analysts Medicinova’s price is currently Overvalued.
Does Medicinova pay dividends?
Medicinova does not currently pay dividends.
What is Medicinova’s EPS estimate?
Medicinova’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicinova have?
Medicinova has 49,146,248 shares outstanding.
What happened to Medicinova’s price movement after its last earnings report?
Medicinova reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.087. Following the earnings report the stock price went down -1.835%.
Which hedge fund is a major shareholder of Medicinova?
Currently, no hedge funds are holding shares in MNOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medicinova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.28%
12-Months-Change
Fundamentals
Return on Equity
-24.26%
Trailing 12-Months
Asset Growth
-18.14%
Trailing 12-Months
Company Description
Medicinova
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Technical Analysis
Precision BioSciences
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Acrivon Therapeutics, Inc.
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
2.88%
Insiders
2.56% Mutual Funds
2.41% Other Institutional Investors
90.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---